Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2008
01/01/2008US7314887 Thrombopoietin activity modulating compounds and methods
01/01/2008US7314886 Tetrahydropyrano-indole derivatives
01/01/2008US7314885 (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase
01/01/2008US7314884 non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile
01/01/2008US7314883 (+-)-3-(1H-Indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid to treat neurogenic vasodilation, neurogenic inflammaton, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases
01/01/2008US7314882 Benzyl 2-oxo-6-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-3-ylcarbamate; CB-1 antagonist; regulating appetitive behavior
01/01/2008US7314881 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds
01/01/2008US7314880 Cardioprotective delta opioid receptor agonists and methods of using same
01/01/2008US7314879 N-Acylpiperazine derivatives for obesity, diabetes, and erectile dysfunction treatment; sexual disorders
01/01/2008US7314878 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders
01/01/2008US7314877 Benzofuran derivative
01/01/2008US7314876 Administering to mammals nitrogen compounds, as mitogen activated kinase inhibitors, for prophylaxis asthma, respiratory system disorders, graft versus host disease, atherosclerosis and arthritis
01/01/2008US7314875 Tricyclic aromatic and bis-phenyl sulfinyl derivatives
01/01/2008US7314874 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo
01/01/2008US7314873 (Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents
01/01/2008US7314872 Selective in presence of at least one other cathepsin isozyme; such as morpholine-4-carboxylic acid {2-cyclopentyl-1--[2-(4-methoxy-phenylamino)-1--methyl-ethylcarbamoyl]-ethyl}-amide
01/01/2008US7314871 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension
01/01/2008US7314870 Compounds, their preparation and use
01/01/2008US7314869 Vaccine vector comprising isolated nucleic acid molecule which encodes sequence 2 linked to promoter
01/01/2008US7314868 fusing cells; nucleic acid vector comprises a nucleotide sequence encoding a measles virus F glycoprotein and a nucleotide sequence encoding a chimeric measles virus H glycoprotein; nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface
01/01/2008US7314862 Antitumor agent
01/01/2008US7314860 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
01/01/2008US7314742 Immunoassay diagnosis of susceptibility to atherosclerosis by analyzing blood for presence of enzyme using polyclonal or monoclonal antibodies; elevated levels are indicative of susceptibility
01/01/2008US7314643 Soft capsule preparation
01/01/2008US7314642 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
01/01/2008US7314640 Formulation and process for drug loaded cores
01/01/2008US7314638 Preparing method for controlled released type tablet tamsulosin HCL and the tablet thereof
01/01/2008US7314634 Use of polyphenols to treat skin conditions
01/01/2008US7314633 Carboxylate-gated-nitroxide (CGN) compounds and compositions and methods of use thereof
01/01/2008US7314627 Cationic lipid-mediated enhancement of nucleic acid immunization of cats
01/01/2008US7314618 Novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosis of
01/01/2008US7314617 Platelet rich plasma, no exogenous activator; sodium bicarbonate buffer, citrate dextrose anticoagulant
01/01/2008US7314612 Cosmetic compositions containing at least one heteropolymer and at least one gelling agent and methods of using the same
01/01/2008US7314484 Methods and devices for treating aneurysms
12/2007
12/30/2007CA2593613A1 Novel naphthalene derivatives, process for their preparation and pharmaceutical compositions containing them
12/30/2007CA2592727A1 Nanoparticulate and controlled release compositions comprising a cephalosporin
12/30/2007CA2558160A1 Antisense oligonucleotides for treatment of muscle wasting
12/27/2007WO2007150075A2 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
12/27/2007WO2007150074A2 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
12/27/2007WO2007150064A2 METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
12/27/2007WO2007150063A2 Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
12/27/2007WO2007150026A2 Purinone derivatives as hm74a agonists
12/27/2007WO2007150018A2 Steroid-containing sustained release intraocular implants and related methods
12/27/2007WO2007150016A2 Il-8 receptor antagonist
12/27/2007WO2007150015A2 Method of treatment
12/27/2007WO2007150011A2 Prolyl hydroxylase inhibitors
12/27/2007WO2007150010A2 Cyclopropyl amine derivatives as histamin h3 receptor modulators
12/27/2007WO2007150002A2 PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE
12/27/2007WO2007150001A1 Pyrro[1,2-b]pyridazinone compounds
12/27/2007WO2007149935A2 Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
12/27/2007WO2007149929A1 Piperidine derivatives for the treatment of gastrointestinal and cns disorders
12/27/2007WO2007149907A2 Pyrazoloquinazolinones as parp inhibitors
12/27/2007WO2007149891A2 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
12/27/2007WO2007149874A1 Imidazolidinone kv1.5 potassium channel inhibitors
12/27/2007WO2007149865A2 Methods and compositions related to inhibition of ceramide synthesis
12/27/2007WO2007149816A2 Strontium compositions and methods of treating osteoporotic conditions
12/27/2007WO2007149815A1 Strontium compositions and methods of treating arthritic and or osteoporitic conditions
12/27/2007WO2007149797A2 Use of organic compounds
12/27/2007WO2007149782A2 Selective inhibitors for transferases
12/27/2007WO2007149568A2 N- (4-chl0r0-3-methyl-5-is0xaz0lyl) -2- [2-methyl-4, 5- (methylenedioxy) phenylacetyl] -thiophene-3-sulfonamide
12/27/2007WO2007149557A1 FUSED [d]PYRIDAZIN-7-ONES
12/27/2007WO2007149529A2 Thrombopoietic compounds
12/27/2007WO2007149512A2 Peptide epoxyketones for pr0teas0me inhibition
12/27/2007WO2007149508A2 Non-competitive nmda receptor antagonists
12/27/2007WO2007149500A2 Formulations containing hybrid dendrimers
12/27/2007WO2007149456A2 Methods and compositions for diagnostic and therapeutic targeting of cox-2
12/27/2007WO2007149451A2 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
12/27/2007WO2007149448A2 Pyrazinones as cellular proliferation inhibitors
12/27/2007WO2007149427A2 Tyrosine kinase inhibitors
12/27/2007WO2007149395A2 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
12/27/2007WO2007149392A1 Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
12/27/2007WO2007149382A2 Therapeutic compositions and methods useful in treating hepatitis
12/27/2007WO2007149366A1 Prolonged improvement of renal function comprising infrequent administration of an aa1ra
12/27/2007WO2007149313A1 Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
12/27/2007WO2007149285A2 Method of improved diuresis in individuals with impaired renal function
12/27/2007WO2007149272A1 Formulation for hair growth
12/27/2007WO2007149211A1 Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
12/27/2007WO2007149163A2 Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
12/27/2007WO2007149119A1 Water stabilized aerosol formulation system and method of making
12/27/2007WO2007149033A1 Substituted isoindoles as bace inhibitors and their use
12/27/2007WO2007149031A1 Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases
12/27/2007WO2007149030A1 Novel heteroaryl substituted benzoxazoles
12/27/2007WO2007148950A1 Synergistic pharmaceutical composition of ketorolac and lysine clonixinate
12/27/2007WO2007148837A1 Composition capable of promoting the production of collagen
12/27/2007WO2007148835A1 Agent for overcoming resistance to anti-cancer agent
12/27/2007WO2007148808A1 Tricyclic compound and pharmaceutical use thereof
12/27/2007WO2007148806A1 Methods of using a thiazole derivative
12/27/2007WO2007148804A1 Composition capable of promoting the production of hyaluronic acid
12/27/2007WO2007148803A1 Composition capable of promoting the production of hyaluronic acid
12/27/2007WO2007148798A1 Reduced coenzyme q10-containing composition and method for producing the same
12/27/2007WO2007148787A1 Process for production of a polymorph of 2-(3-cyano-4- isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid
12/27/2007WO2007148786A1 Stabilized solid preparation
12/27/2007WO2007148780A1 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor
12/27/2007WO2007148775A1 Chain amine compound
12/27/2007WO2007148774A1 Cyclic amine compound
12/27/2007WO2007148772A1 Sugar-coated reparation of macrolide antibiotic
12/27/2007WO2007148752A1 Infusion preparation for dialysis patient
12/27/2007WO2007148744A1 Prophylactic or therapeutic agent for corneal/conjunctival disorder comprising fumaric acid derivative as active ingredient
12/27/2007WO2007148714A1 Implant using rifamycin derivative
12/27/2007WO2007148713A1 Drug for treating vascular disease or drug for controlling cell proliferation comprising rifamycin derivative as the active ingredient